Salubris Enters Drug Distribution Business With Shenzhen Acquisition
This article was originally published in PharmAsia News
Salubris announced it acquired 100% equity of Shenzhen Jianshankang Pharmaceuticals for RMB 2 million, and would continue Jianshankang’s operations as a qualified pharmaceutical distributor.
You may also be interested in...
From efficacy endpoints to patient warehousing, US FDA advisors weigh in on vaccine development and regulatory review.
Several years ago, heart device giant Edwards Lifesciences realized it needed a new CAPA framework that shifts corrective and preventive action from a one-size-fits-all method to a more nuanced approach. See what Dan Buehner, director of quality engineering at Edwards Lifesciences, said about it here.
FDA's recommendation that COVID-19 vaccine sponsors conduct two months of median follow-up to support an emergency use authorization may not be long enough, some experts say in what can be viewed as validation for agency's position in battle with White House.